Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I trial of PCNU.

L A Kalman, R J Gralla, E S Casper

    Cancer Treatment Reports
    |November 1, 1983
    PubMed
    Summary

    This phase I trial investigated PCNU in advanced solid tumors. Myelosuppression was dose-limiting, with no observed antitumor activity, recommending a specific dose range for further studies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Canine meningitis and meningoencephalitis in eastern Australia.

    Australian veterinary journal·2025
    Same author

    Lumbar nerve root compression resulting from extrusion of intervertebral disc material after prophylactic disc fenestration.

    Australian veterinary journal·2025
    Same author

    Reply to: Concerns regarding proposed groundwater Earth system boundary.

    Nature·2024
    Same author

    The Impact of Hearing Aids on Listening Effort and Listening-Related Fatigue - Investigations in a Virtual Realistic Listening Environment.

    Trends in hearing·2024
    Same author

    Pandemic lockdowns: who feels coerced and why? - a study on perceived coercion, perceived pressures and procedural justice during the UK COVID-19 lockdowns.

    BMC public health·2024
    Same author

    Developing a Pipeline of African Global Surgery Scholars.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2023

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Advanced solid tumors present significant treatment challenges.
    • Novel chemotherapeutic agents are continuously evaluated for efficacy and safety.
    • PCNU is a nitrosourea derivative with potential anticancer properties.

    Purpose of the Study:

    • To evaluate the safety and tolerability of PCNU in patients with advanced solid tumors.
    • To determine the dose-limiting toxicity of PCNU.
    • To establish a recommended dose for future phase II trials.

    Main Methods:

    • A phase I, dose-escalation study was conducted.
    • Twenty-eight patients with advanced solid tumors received PCNU intravenously over 5 days every 6 weeks.
    • Doses ranged from 25 to 150 mg/m2 across six escalation steps.

    Main Results:

    • Myelosuppression, particularly thrombocytopenia, was dose-limiting, observed at doses >= 82.5 mg/m2.
    • Leukopenia occurred at higher doses; nausea was uncommon, and vomiting did not occur.
    • No adverse effects on renal or hepatic function were noted, and no antitumor activity was observed.

    Conclusions:

    • PCNU demonstrated dose-limiting myelosuppression in this phase I trial.
    • A recommended dose range of 100-125 mg/m2 (20-25 mg/m2/day) for 5-day courses is suggested for phase II studies.
    • Further investigation is warranted to explore potential therapeutic benefits despite the lack of observed antitumor activity in this initial study.

    Related Experiment Videos